Zacks: Brokerages Set $45.00 Target Price for Odonate Therapeutics Inc (NASDAQ:ODT)

Share on StockTwits

Shares of Odonate Therapeutics Inc (NASDAQ:ODT) have earned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.

Brokers have set a one year consensus price target of $45.00 for the company and are predicting that the company will post ($1.08) earnings per share for the current quarter, according to Zacks. Zacks has also given Odonate Therapeutics an industry rank of 58 out of 255 based on the ratings given to its competitors.

ODT has been the topic of a number of recent analyst reports. ValuEngine downgraded shares of Odonate Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Zacks Investment Research downgraded shares of Odonate Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, November 12th.

Several hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC raised its stake in shares of Odonate Therapeutics by 106.9% during the second quarter. Tower Research Capital LLC TRC now owns 1,703 shares of the company’s stock worth $63,000 after acquiring an additional 880 shares in the last quarter. Meeder Asset Management Inc. grew its holdings in shares of Odonate Therapeutics by 198.7% in the second quarter. Meeder Asset Management Inc. now owns 1,574 shares of the company’s stock worth $57,000 after purchasing an additional 1,047 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Odonate Therapeutics by 2.1% in the second quarter. Charles Schwab Investment Management Inc. now owns 55,205 shares of the company’s stock worth $2,026,000 after purchasing an additional 1,150 shares during the last quarter. Barclays PLC grew its holdings in shares of Odonate Therapeutics by 21.8% in the third quarter. Barclays PLC now owns 9,109 shares of the company’s stock worth $236,000 after purchasing an additional 1,632 shares during the last quarter. Finally, Chartwell Investment Partners LLC grew its holdings in shares of Odonate Therapeutics by 6.2% in the second quarter. Chartwell Investment Partners LLC now owns 30,543 shares of the company’s stock worth $1,121,000 after purchasing an additional 1,782 shares during the last quarter. 98.04% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ:ODT traded up $1.70 on Wednesday, reaching $34.98. 124,251 shares of the company’s stock were exchanged, compared to its average volume of 92,523. The stock has a fifty day simple moving average of $32.50 and a 200-day simple moving average of $30.95. Odonate Therapeutics has a 52 week low of $11.54 and a 52 week high of $43.75. The firm has a market cap of $1.10 billion, a price-to-earnings ratio of -9.61 and a beta of 1.83.

Odonate Therapeutics (NASDAQ:ODT) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.19. On average, equities analysts predict that Odonate Therapeutics will post -4.23 EPS for the current fiscal year.

About Odonate Therapeutics

Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.

Further Reading: What sectors are represented in the FTSE 100 index?

Get a free copy of the Zacks research report on Odonate Therapeutics (ODT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.